Raymond James & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $895M | Buy |
4,533,099
+26,954
| +0.6% | +$5.03M | 0.55% | 29 |
|
|
2024
Q2 | $773M | Buy |
4,506,145
+184,749
| +4% | +$30.6M | 0.51% | 34 |
|
|
2024
Q1 | $787M | Sell |
4,321,396
-187,976
| -4% | -$32.4M | 0.53% | 30 |
|
|
2023
Q4 | $699M | Buy |
4,509,372
+79,019
| +2% | +$11.5M | 0.52% | 32 |
|
|
2023
Q3 | $660M | Buy |
4,430,353
+92,342
| +2% | +$13.6M | 0.55% | 30 |
|
|
2023
Q2 | $584M | Sell |
4,338,011
-309,586
| -7% | -$45.4M | 0.48% | 34 |
|
|
2023
Q1 | $741M | Buy |
4,647,597
+158,105
| +4% | +$24.2M | 0.64% | 22 |
|
|
2022
Q4 | $726M | Buy |
4,489,492
+525,233
| +13% | +$80.5M | 0.67% | 18 |
|
|
2022
Q3 | $532M | Buy |
3,964,259
+170,536
| +4% | +$24.5M | 0.54% | 28 |
|
|
2022
Q2 | $581M | Sell |
3,793,723
-350,530
| -8% | -$53.6M | 0.57% | 24 |
|
|
2022
Q1 | $672M | Buy |
4,144,253
+95,362
| +2% | +$13.9M | 0.57% | 27 |
|
|
2021
Q4 | $548M | Buy |
4,048,891
+88,704
| +2% | +$10.5M | 0.44% | 36 |
|
|
2021
Q3 | $427M | Buy |
3,960,187
+217,112
| +6% | +$24.8M | 0.38% | 42 |
|
|
2021
Q2 | $422M | Buy |
3,743,075
+162,640
| +5% | +$18.3M | 0.38% | 43 |
|
|
2021
Q1 | $387M | Sell |
3,580,435
-17,866
| -0.5% | -$1.91M | 0.39% | 44 |
|
|
2020
Q4 | $386M | Buy |
3,598,301
+359,157
| +11% | +$34.5M | 0.42% | 44 |
|
|
2020
Q3 | $284M | Sell |
3,239,144
-54,852
| -2% | -$5.16M | 0.35% | 54 |
|
|
2020
Q2 | $323M | Buy |
3,293,996
+102,200
| +3% | +$9M | 0.43% | 42 |
|
|
2020
Q1 | $243M | Buy |
3,191,796
+27,560
| +0.9% | +$2.35M | 0.39% | 48 |
|
|
2019
Q4 | $280M | Buy |
3,164,236
+115,011
| +4% | +$9.55M | 0.36% | 51 |
|
|
2019
Q3 | $231M | Buy |
3,049,225
+369,192
| +14% | +$25.3M | 0.32% | 53 |
|
|
2019
Q2 | $195M | Sell |
2,680,033
-1,703,375
| -39% | -$134M | 0.28% | 59 |
|
|
2019
Q1 | $353M | Buy |
4,383,408
+375,464
| +9% | +$30.7M | 0.54% | 30 |
|
|
2018
Q4 | $369M | Buy |
4,007,944
+472,550
| +13% | +$41.6M | 0.64% | 22 |
|
|
2018
Q3 | $334M | Buy |
3,535,394
+134,234
| +4% | +$12.7M | 0.52% | 29 |
|
|
2018
Q2 | $315M | Buy |
3,401,160
+108,230
| +3% | +$10.6M | 0.53% | 28 |
|
|
2018
Q1 | $312M | Sell |
3,292,930
-620,233
| -16% | -$68.1M | 0.56% | 23 |
|
|
2017
Q4 | $378M | Sell |
3,913,163
-529,915
| -12% | -$49.9M | 0.7% | 17 |
|
|
2017
Q3 | $395M | Sell |
4,443,078
-750,093
| -14% | -$57.1M | 0.79% | 12 |
|
|
2017
Q2 | $377M | Buy |
5,193,171
+480,934
| +10% | +$32.3M | 0.81% | 12 |
|
|
2017
Q1 | $307M | Buy |
4,712,237
+831,502
| +21% | +$52.3M | 0.71% | 15 |
|
|
2016
Q4 | $243M | Buy |
3,880,735
+893,454
| +30% | +$54.5M | 0.62% | 20 |
|
|
2016
Q3 | $188M | Buy |
2,987,281
+860,679
| +40% | +$55.7M | 0.51% | 29 |
|
|
2016
Q2 | $132M | Buy |
2,126,602
+98,278
| +5% | +$5.99M | 0.41% | 44 |
|
|
2016
Q1 | $116M | Buy |
2,028,324
+1,027,917
| +103% | +$57.3M | 0.39% | 44 |
|
|
2015
Q4 | $59.3M | Buy |
1,000,407
+179,455
| +22% | +$10.3M | 0.21% | 100 |
|
|
2015
Q3 | $44.7M | Buy |
820,952
+116,754
| +17% | +$7.6M | 0.18% | 119 |
|
|
2015
Q2 | $47.3M | Sell |
704,198
-189,998
| -21% | -$12.4M | 0.18% | 113 |
|
|
2015
Q1 | $52.3M | Buy |
894,196
+97,243
| +12% | +$5.87M | 0.23% | 90 |
|
|
2014
Q4 | $52.2M | Buy |
796,953
+127,065
| +19% | +$8.01M | 0.25% | 76 |
|
|
2014
Q3 | $38.7M | Sell |
669,888
-95,506
| -12% | -$5.3M | 0.22% | 78 |
|
|
2014
Q2 | $43.2M | Buy |
765,394
+42,929
| +6% | +$2.25M | 0.27% | 58 |
|
|
2014
Q1 | $37.1M | Sell |
722,465
-203,586
| -22% | -$10.3M | 0.25% | 66 |
|
|
2013
Q4 | $48.9M | Buy |
926,051
+99,362
| +12% | +$4.88M | 0.37% | 46 |
|
|
2013
Q3 | $37M | Sell |
826,689
-10,436
| -1% | -$463K | 0.32% | 53 |
|
|
2013
Q2 | $34.6M | Buy |
+837,125
| New | +$36.6M | 0.33% | 54 |
|
Other funds holding ABBV
Raymond James & Associates's ABBV Position: Q3 2024 in Review
Raymond James & Associates increased its AbbVie (ABBV) stake by 0.6% in Q3 2024, buying an estimated $5.03M and bringing the position to 4,533,099 shares worth $895M. The position accounts for 0.55% of the portfolio, ranked #29.
Raymond James & Associates first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. 3,498 funds tracked by Wall St. Rank hold ABBV as of Q3 2024.
- Raymond James & Associates held 4,533,099 shares of AbbVie worth $895M as of Q3 2024.
- Raymond James & Associates bought 26,954 AbbVie shares in Q3 2024, an estimated $5.03M.
- AbbVie made up 0.55% of Raymond James & Associates's portfolio in Q3 2024, its #29 holding.
- Raymond James & Associates first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
- 3,498 funds tracked by Wall St. Rank held AbbVie as of Q3 2024.
Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.